Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection (NASDAQ:LYEL)
· seekingalpha.com
Lyell Immunopharma (LYLE) offers asymmetric upside, with ronde-cel showing best-in-class durability and safety in relapsed/refractory LBCL.
The buy case for Lyell Immunopharma (LYLE) would hinge on a derisked regulatory path combined with asymmetric upside. We know that ronde-cel already exceeds the...